RxDoctor Payments Data

Melissa Morales Garcia, MD

Neurology · San Juan, PRNPI 1063901304

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 24.9% of the total. 2025 is the largest year on record at $618, 2.6 times the $237 reported in 2019.

$1,894in general payments, 2019–2025

Across 36 payments — averaging $52.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$471
  • Teva Pharmaceuticals USA, Inc.$203
  • EMD Serono, Inc.$135
  • Amneal Pharmaceuticals LLC$127
  • Eisai Inc.$124
  • E.r. Squibb & Sons, L.L.C.$115
  • plus $719 from 13 others

What the payments were for

  • Food & beverage$1,894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,894 in reported general payments places this provider in the 55th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$17,940
Medicare patients
64
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa31$20,755
Carbidopa-LevodopaCarbidopa/Levodopa481$16,188
Rivastigmine45$6,524
Memantine Hcl ErMemantine Hcl69$6,020
Carbidopa17$5,162
Memantine Hcl225$4,784
Mirtazapine76$3,654
Galantamine ErGalantamine Hbr29$3,285
Primidone86$2,927
Propranolol Hcl117$2,494
Entacapone22$2,405
RivastigmineRivastigmine Tartrate54$2,387
Donepezil Hcl207$2,265
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone12$2,025
Carbidopa-Levodopa ErCarbidopa/Levodopa50$1,807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$127$20,75531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →